These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
141 related articles for article (PubMed ID: 34649259)
1. Neuropeptide Cortistatin Regulates Dermal and Pulmonary Fibrosis in an Experimental Model of Systemic Sclerosis. Barriga M; Benitez R; Robledo G; Caro M; O'Valle F; Campos-Salinas J; Delgado M Neuroendocrinology; 2022; 112(8):784-795. PubMed ID: 34649259 [TBL] [Abstract][Full Text] [Related]
2. Protective role of cortistatin in pulmonary inflammation and fibrosis. Barriga M; Benitez R; Ferraz-de-Paula V; Garcia-Frutos M; Caro M; Robledo G; O'Valle F; Campos-Salinas J; Delgado M Br J Pharmacol; 2021 Nov; 178(21):4368-4388. PubMed ID: 34237151 [TBL] [Abstract][Full Text] [Related]
3. TRPA1 as a potential factor and drug target in scleroderma: dermal fibrosis and alternative macrophage activation are attenuated in TRPA1-deficient mice in bleomycin-induced experimental model of scleroderma. Mäki-Opas I; Hämäläinen M; Moilanen E; Scotece M Arthritis Res Ther; 2023 Jan; 25(1):12. PubMed ID: 36698198 [TBL] [Abstract][Full Text] [Related]
4. CD109 overexpression ameliorates skin fibrosis in a mouse model of bleomycin-induced scleroderma. Vorstenbosch J; Al-Ajmi H; Winocour S; Trzeciak A; Lessard L; Philip A Arthritis Rheum; 2013 May; 65(5):1378-83. PubMed ID: 23436317 [TBL] [Abstract][Full Text] [Related]
5. Cortistatin regulates fibrosis and myofibroblast activation in experimental hepatotoxic- and cholestatic-induced liver injury. Benitez R; Caro M; Andres-Leon E; O'Valle F; Delgado M Br J Pharmacol; 2022 May; 179(10):2275-2296. PubMed ID: 34821378 [TBL] [Abstract][Full Text] [Related]
6. Scleroderma-like Impairment in the Network of Telocytes/CD34 Rosa I; Romano E; Fioretto BS; Guasti D; Ibba-Manneschi L; Matucci-Cerinic M; Manetti M Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830288 [TBL] [Abstract][Full Text] [Related]
7. Th17 cells and IL-17 promote the skin and lung inflammation and fibrosis process in a bleomycin-induced murine model of systemic sclerosis. Lei L; Zhao C; Qin F; He ZY; Wang X; Zhong XN Clin Exp Rheumatol; 2016; 34 Suppl 100(5):14-22. PubMed ID: 26750756 [TBL] [Abstract][Full Text] [Related]
8. Elevated frequencies of CD4(+) IL-21(+) T, CD4(+) IL-21R(+) T and IL-21(+) Th17 cells, and increased levels of IL-21 in bleomycin-induced mice may be associated with dermal and pulmonary inflammation and fibrosis. Lei L; He ZY; Zhao C; Sun XJ; Zhong XN Int J Rheum Dis; 2016 Apr; 19(4):392-404. PubMed ID: 25545680 [TBL] [Abstract][Full Text] [Related]
9. DZ2002 ameliorates fibrosis, inflammation, and vasculopathy in experimental systemic sclerosis models. Zhang Z; Wu Y; Wu B; Qi Q; Li H; Lu H; Fan C; Feng C; Zuo J; Niu L; Tang W Arthritis Res Ther; 2019 Dec; 21(1):290. PubMed ID: 31842999 [TBL] [Abstract][Full Text] [Related]
10. Inhibition of the Progression of Skin Inflammation, Fibrosis, and Vascular Injury by Blockade of the CX Luong VH; Utsunomiya A; Chino T; Doanh LH; Matsushita T; Obara T; Kuboi Y; Ishii N; Machinaga A; Ogasawara H; Ikeda W; Kawano T; Imai T; Oyama N; Hasegawa M Arthritis Rheumatol; 2019 Nov; 71(11):1923-1934. PubMed ID: 31173491 [TBL] [Abstract][Full Text] [Related]
11. Amelioration of dermal fibrosis by genetic deletion or pharmacologic antagonism of lysophosphatidic acid receptor 1 in a mouse model of scleroderma. Castelino FV; Seiders J; Bain G; Brooks SF; King CD; Swaney JS; Lorrain DS; Chun J; Luster AD; Tager AM Arthritis Rheum; 2011 May; 63(5):1405-15. PubMed ID: 21305523 [TBL] [Abstract][Full Text] [Related]
12. Animal model of sclerotic skin. II. Bleomycin induced scleroderma in genetically mast cell deficient WBB6F1-W/W(V) mice. Yamamoto T; Takahashi Y; Takagawa S; Katayama I; Nishioka K J Rheumatol; 1999 Dec; 26(12):2628-34. PubMed ID: 10606374 [TBL] [Abstract][Full Text] [Related]
13. MKP-1 Deficiency Exacerbates Skin Fibrosis in a Mouse Model of Scleroderma. Scotece M; Hämäläinen M; Leppänen T; Vuolteenaho K; Moilanen E Int J Mol Sci; 2023 Feb; 24(5):. PubMed ID: 36902103 [TBL] [Abstract][Full Text] [Related]
14. Secukinumab and metformin ameliorate dermal fibrosis by decreasing tissue interleukin-17 levels in bleomycin-induced dermal fibrosis. Karatas A; Celik C; Oz B; Akar ZA; Etem EO; Dagli AF; Koca SS Int J Rheum Dis; 2021 Jun; 24(6):795-802. PubMed ID: 33835703 [TBL] [Abstract][Full Text] [Related]
15. A modified murine model of systemic sclerosis: bleomycin given by pump infusion induced skin and pulmonary inflammation and fibrosis. Liang M; Lv J; Zou L; Yang W; Xiong Y; Chen X; Guan M; He R; Zou H Lab Invest; 2015 Mar; 95(3):342-50. PubMed ID: 25502178 [TBL] [Abstract][Full Text] [Related]
16. Dipeptidylpeptidase 4 as a Marker of Activated Fibroblasts and a Potential Target for the Treatment of Fibrosis in Systemic Sclerosis. Soare A; Györfi HA; Matei AE; Dees C; Rauber S; Wohlfahrt T; Chen CW; Ludolph I; Horch RE; Bäuerle T; von Hörsten S; Mihai C; Distler O; Ramming A; Schett G; Distler JHW Arthritis Rheumatol; 2020 Jan; 72(1):137-149. PubMed ID: 31350829 [TBL] [Abstract][Full Text] [Related]
17. CD19 regulates skin and lung fibrosis via Toll-like receptor signaling in a model of bleomycin-induced scleroderma. Yoshizaki A; Iwata Y; Komura K; Ogawa F; Hara T; Muroi E; Takenaka M; Shimizu K; Hasegawa M; Fujimoto M; Tedder TF; Sato S Am J Pathol; 2008 Jun; 172(6):1650-63. PubMed ID: 18467694 [TBL] [Abstract][Full Text] [Related]
18. The involvement of leucine-rich α-2 glycoprotein in the progression of skin and lung fibrosis in bleomycin-induced systemic sclerosis model. Nakajima H; Nakajima K; Serada S; Fujimoto M; Naka T; Sano S Mod Rheumatol; 2021 Nov; 31(6):1120-1128. PubMed ID: 33535851 [TBL] [Abstract][Full Text] [Related]